<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392677</url>
  </required_header>
  <id_info>
    <org_study_id>D1693C00005</org_study_id>
    <nct_id>NCT01392677</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea</brief_title>
  <official_title>A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to compare the efficacy and safety of dapagliflozin versus placebo in
      patients with type 2 diabetes who have inadequate glycaemic control on a background
      combination of metformin and sulfonylurea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change From Baseline in HbA1c Levels</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To compare the change from baseline in HbA1c to week 24 between dapagliflozin 10 mg in combination with metformin and sulfonylurea and placebo in combination with metformin and sulfonylurea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in FPG</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To compare the change from baseline in fasting plasma glucose (FPG) to week 24 (LOCF) between dapagliflozin and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Total Body Weight</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To compare the change from baseline in total body weight to week 24 (LOCF) between dapagliflozin and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HbA1c Value &lt; 7.0% at Week 24 (LOCF)</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To compare the proportion of subjects achieving a therapeutic glycemic response, defined as HbA1c &lt;7.0%, at week 24 (LOCF) between dapagliflozin and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure</measure>
    <time_frame>Baseline to week 8</time_frame>
    <description>To compare the change from baseline in seated systolic blood pressure (SBP) to week 8 (LOCF) between dapagliflozin and placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>High HbA1c Level</condition>
  <condition>Inadequate Glycaemic Control</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapagliflozin</intervention_name>
    <description>10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period</description>
    <arm_group_label>Dapagliflozin 10 mg tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period</description>
    <arm_group_label>matching placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Men or women age ≥ 18 years old

          -  Stable dose combination of metformin and sulfonylurea

          -  HbA1c ≥7.7% and ≤11.0%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or diabetes insipidus

          -  Recent cardiovascular events

          -  Kidney or urological disorders

          -  Hepatic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Johnsson, PhD, Medical Science Director</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Global Medicines Development CVGI, SE-431 83 Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Matthaei, Prof.Dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes-Zentrum Quakenbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney Mines</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kensington</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beroun</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jilove U Prahy</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 6</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Semily</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vyskov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asslar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aßlar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falkensee</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pirna</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sta Coloma de Gramanet (bcn)</city>
        <state>Catalu?a</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sta Coloma de Gramenet (BCN)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1200&amp;filename=D1693C00005.pdf</url>
    <description>D1693C00005.pdf</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <results_first_submitted>November 5, 2013</results_first_submitted>
  <results_first_submitted_qc>November 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 27, 2013</results_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dapagliflozin</keyword>
  <keyword>diabetes</keyword>
  <keyword>hyperglycaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant enrolled: 24 Oct 2011. Last participant completed 24 week period: 07 Jan 2013. 311 participants were enrolled, 219 were randomized in 45 centers in 5 European countries and in North America. Men and women aged &gt;= 18 years with inadequate glycemic control (HbA1c 7.0% to 10.5% prior to randomization).</recruitment_details>
      <pre_assignment_details>During enrollment, diet and life-style advice was given to participants and was reinforced during a placebo lead-in period. Dose of anti-hyperglycemic combination therapy of metformin &gt;= 1500 mg/day and maximum tolerated dose which must be at least half the maximum dose of sulfonylurea for at least 8 weeks prior to enrollment were to remain stable.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Plus Metformin Plus Sulfonylurea</title>
          <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
          <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrollment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of study medication during the 24-week short-term double blind treatment period who have a non-missing baseline value and at least one post-baseline value for at least one efficacy variable to be analyzed at week 24.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Plus Metformin Plus Sulfonylurea</title>
          <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
          <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="9.24"/>
                    <measurement group_id="B2" value="61.1" spread="9.65"/>
                    <measurement group_id="B3" value="61.0" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.07" spread="16.175"/>
                    <measurement group_id="B2" value="88.57" spread="17.584"/>
                    <measurement group_id="B3" value="89.32" spread="16.872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.02" spread="4.581"/>
                    <measurement group_id="B2" value="31.93" spread="4.840"/>
                    <measurement group_id="B3" value="31.97" spread="4.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated hemoglobin A1c (HbA1c)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.24" spread="0.865"/>
                    <measurement group_id="B2" value="8.08" spread="0.912"/>
                    <measurement group_id="B3" value="8.16" spread="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180.2" spread="43.13"/>
                    <measurement group_id="B2" value="167.4" spread="43.32"/>
                    <measurement group_id="B3" value="173.8" spread="43.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting C-Peptide</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="0.98"/>
                    <measurement group_id="B2" value="2.5" spread="1.06"/>
                    <measurement group_id="B3" value="2.5" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change From Baseline in HbA1c Levels</title>
        <description>To compare the change from baseline in HbA1c to week 24 between dapagliflozin 10 mg in combination with metformin and sulfonylurea and placebo in combination with metformin and sulfonylurea.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and week 24 values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Metformin Plus Sulfonylurea</title>
            <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
            <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in HbA1c Levels</title>
          <description>To compare the change from baseline in HbA1c to week 24 between dapagliflozin 10 mg in combination with metformin and sulfonylurea and placebo in combination with metformin and sulfonylurea.</description>
          <population>Full Analysis Set, participants with non-missing baseline and week 24 values</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-0.31" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-0.86" lower_limit="-1.00" upper_limit="-0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (2-sided). A hierarchical closed testing procedure was used to control Type I error across the primary &amp; key secondary objectives</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Longitudinal repeated measures model using mixed model with treatment group, baseline value, week and week*treatment and week*baseline</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in FPG</title>
        <description>To compare the change from baseline in fasting plasma glucose (FPG) to week 24 (LOCF) between dapagliflozin and placebo</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and week 24 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Metformin Plus Sulfonylurea</title>
            <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
            <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in FPG</title>
          <description>To compare the change from baseline in fasting plasma glucose (FPG) to week 24 (LOCF) between dapagliflozin and placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and week 24 (LOCF) values</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" lower_limit="-7.56" upper_limit="6.01"/>
                    <measurement group_id="O2" value="-34.23" lower_limit="-40.98" upper_limit="-27.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (2-sided). A hierarchical closed testing procedure was used to control Type I error across the primary &amp; key secondary objectives</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group as effect and baseline value as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8846</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.08</ci_lower_limit>
            <ci_upper_limit>-23.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Total Body Weight</title>
        <description>To compare the change from baseline in total body weight to week 24 (LOCF) between dapagliflozin and placebo</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and week 24 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Metformin Plus Sulfonylurea</title>
            <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
            <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Total Body Weight</title>
          <description>To compare the change from baseline in total body weight to week 24 (LOCF) between dapagliflozin and placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and week 24 (LOCF) values</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" lower_limit="-1.09" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-2.65" lower_limit="-3.16" upper_limit="-2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (2-sided). A hierarchical closed testing procedure was used to control Type I error across the primary &amp; key secondary objectives</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group as effect and baseline value as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3651</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.79</ci_lower_limit>
            <ci_upper_limit>-1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HbA1c Value &lt; 7.0% at Week 24 (LOCF)</title>
        <description>To compare the proportion of subjects achieving a therapeutic glycemic response, defined as HbA1c &lt;7.0%, at week 24 (LOCF) between dapagliflozin and placebo</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and week 24 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Metformin Plus Sulfonylurea</title>
            <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
            <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HbA1c Value &lt; 7.0% at Week 24 (LOCF)</title>
          <description>To compare the proportion of subjects achieving a therapeutic glycemic response, defined as HbA1c &lt;7.0%, at week 24 (LOCF) between dapagliflozin and placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and week 24 (LOCF) values</population>
          <units>Percentage of participants</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="5.4" upper_limit="16.8"/>
                    <measurement group_id="O2" value="31.8" lower_limit="23.3" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: proportion(treat) minus proportion (placebo) = 0 versus the alternative HA: proportion (treat) minus proportion (placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significant at alpha=0.05 (2-sided). A hierarchical closed testing procedure was used to control Type I error across the primary &amp; key secondary objectives</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Based on methodology of Zhang, Tsiatis &amp; Davidian and Tsiatis, Davidian, Zhang &amp; Lu, with adjustment for baseline value</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.7</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure</title>
        <description>To compare the change from baseline in seated systolic blood pressure (SBP) to week 8 (LOCF) between dapagliflozin and placebo</description>
        <time_frame>Baseline to week 8</time_frame>
        <population>Full Analysis Set, participants with non-missing baseline and week 8 (LOCF) values</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Metformin Plus Sulfonylurea</title>
            <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
            <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure</title>
          <description>To compare the change from baseline in seated systolic blood pressure (SBP) to week 8 (LOCF) between dapagliflozin and placebo</description>
          <population>Full Analysis Set, participants with non-missing baseline and week 8 (LOCF) values</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-2.60" upper_limit="2.05"/>
                    <measurement group_id="O2" value="-4.04" lower_limit="-6.36" upper_limit="-1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: mean(treat) minus mean(placebo) = 0 versus the alternative HA: mean(treat) minus mean(placebo) =/= 0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>Significant at alpha=0.05 (2-sided). A hierarchical closed testing procedure was used to control Type I error across the primary &amp; key secondary objectives</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>with treatment group as effect and baseline value as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6677</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.05</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious / serious adverse events on or after the first day and on or prior to the last day of the 24-week double-blind treatment plus 4/30 days or up to follow-up visit if earlier, or up to and including the start date of extension period if earlier.</time_frame>
      <desc>Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Plus Metformin Plus Sulfonylurea</title>
          <description>Placebo once daily plus background combination of metformin and sulfonylurea</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea</title>
          <description>Dapagliflozin 10mg once daily plus background combination of metformin and sulfonylurea</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>sympathetic posterior cervical syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For participants who did not complete 8 and/or 24 weeks, respectively, last observation carried forward (LOCF) was used for analyses of secondary endpoints. All endpoints were evaluated by excluding data after rescue.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eva Johnsson</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

